

Sixten Borg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/618612/publications.pdf>

Version: 2024-02-01

27
papers

1,296
citations

567281

15
h-index

526287

27
g-index

27
all docs

27
docs citations

27
times ranked

1808
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 481-489.	1.9	340
2	The costs of exacerbations in chronic obstructive pulmonary disease (COPD). <i>Respiratory Medicine</i> , 2002, 96, 700-708.	2.9	259
3	Costs of COPD in Sweden According to Disease Severity. <i>Chest</i> , 2002, 122, 1994-2002.	0.8	161
4	A Computer Simulation Model of the Natural History and Economic Impact of Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2004, 7, 153-167.	0.3	80
5	Obesity, Survival, and Hospital Costs—Findings from a Screening Project in Sweden. <i>Value in Health</i> , 2005, 8, 562-571.	0.3	48
6	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. <i>Value in Health</i> , 2014, 17, 525-536.	0.3	41
7	Drug and treatment costs in Parkinson’s disease patients in Sweden. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 142-147.	2.1	37
8	Health-related quality of life and glycaemic control among adults with type 1 and type 2 diabetes – a nationwide cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 141.	2.4	36
9	The Impact of Exacerbations on the Asthmatic Patient’s Preference Scores. <i>Journal of Asthma</i> , 2003, 40, 615-623.	1.7	30
10	Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. <i>International Journal of COPD</i> , 2017, Volume 12, 3183-3194.	2.3	30
11	A disease-specific questionnaire for measuring patient-reported outcomes and experiences in the Swedish National Diabetes Register: Development and evaluation of content validity, face validity, and test-retest reliability. <i>Patient Education and Counseling</i> , 2018, 101, 139-146.	2.2	30
12	The Swedish cost burden of overweight and obesity – evaluated with the PAR approach and a statistical modelling approach. <i>Pediatric Obesity</i> , 2008, 3, 51-57.	3.2	22
13	Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. <i>Journal of Medical Economics</i> , 2015, 18, 492-501.	2.1	22
14	Patient-reported outcome and experience measures for diabetes: development of scale models, differences between patient groups and relationships with cardiovascular and diabetes complication risk factors, in a combined registry and survey study in Sweden. <i>BMJ Open</i> , 2019, 9, e025033.	1.9	22
15	Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort. <i>European Journal of Health Economics</i> , 2009, 10, 217-226.	2.8	17
16	Patient-Reported Outcome Measures and Risk Factors in a Quality Registry: A Basis for More Patient-Centered Diabetes Care in Sweden. <i>International Journal of Environmental Research and Public Health</i> , 2014, 11, 12223-12246.	2.6	17
17	Cost Differences for COPD With and Without Physician-Diagnosis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 427-434.	1.6	15
18	Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: Comparative analysis of drug utilization, costs, and hematologic response. <i>Advances in Therapy</i> , 2005, 22, 208-224.	2.9	14

#	ARTICLE	IF	CITATIONS
19	Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. <i>Acta Oncologica</i> , 2016, 55, 554-560.	1.8	14
20	The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: A Markov model. <i>Acta Oncologica</i> , 2008, 47, 1009-1017.	1.8	11
21	Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , 2016, 19, 800-810.	0.3	11
22	Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-Receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: A decision-analytic model. <i>Clinical Therapeutics</i> , 2006, 28, 1947-1959.	2.5	9
23	A Maximum Likelihood Estimator of a Markov Model for Disease Activity in Crohn's Disease and Ulcerative Colitis for Annually Aggregated Partial Observations. <i>Medical Decision Making</i> , 2010, 30, 132-142.	2.4	8
24	Retrospective incremental cost analysis of a hospital-based COPD Disease Management Programme in Sweden. <i>Health Policy</i> , 2007, 81, 309-319.	3.0	7
25	Budget Impact Analysis of Surgical Treatment for Obesity in Sweden. <i>Scandinavian Journal of Surgery</i> , 2012, 101, 190-197.	2.6	7
26	Quality of life in chronic conditions using patient-reported measures and biomarkers: a DEA analysis in type 1 diabetes. <i>Health Economics Review</i> , 2019, 9, 31.	2.0	4
27	New Diabetes Questionnaire to add patients' perspectives to diabetes care for adults with type 1 and type 2 diabetes: nationwide cross-sectional study of construct validity assessing associations with generic health-related quality of life and clinical variables. <i>BMJ Open</i> , 2020, 10, e038966.	1.9	4